Tibor Racz, MD
Interventional Pain Medicine · Rockwall, TXNPI 1942287248
Payments from drug & device makers
Across 478 payments — averaging $46.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$9K
- Medtronic$6K
- Boston Scientific$3K
- Abbott$693
- Collegium Pharmaceutical, Inc.$673
- Biotronik NRO, Inc.$424
- plus $2K from 31 others
What the payments were for
- Consulting fees$8,00036%
- Travel & lodging$6033%
- Food & beverage$10,59548%
- Other$3,10714%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 43 | $9,222 |
| Medtronic(2 entities) | 68 | $5,896 |
| Boston Scientific | 146 | $3,231 |
| Abbott | 19 | $693 |
| Collegium Pharmaceutical, Inc. | 81 | $673 |
| Biotronik NRO, Inc. | 2 | $424 |
| Saluda Medical Americas, Inc. | 9 | $227 |
| Biodelivery Sciences International, Inc. | 31 | $219 |
| Scilex Pharmaceuticals Inc. | 12 | $200 |
| Tersera Therapeutics LLC | 8 | $165 |
| Vertiflex, Inc. | 7 | $147 |
| Curonix LLC | 2 | $116 |
| AbbVie | 4 | $107 |
| Forte Bio-pharma LLC | 3 | $92 |
| Spinal Simplicity, LLC | 4 | $85 |
| Almatica Pharma LLC | 4 | $83 |
| Vertos Medical, Inc. | 2 | $80 |
| Novartis | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $70 |
| Stryker | 1 | $56 |
| Amgen | 2 | $46 |
| Nalu Medical, Inc. | 2 | $37 |
| Arbor Pharmaceuticals, Inc. | 2 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Lilly USA, LLC | 2 | $31 |
| Protega Pharmaceutials Inc | 1 | $28 |
| Virtus Pharmaceuticals LLC | 2 | $28 |
| Vertex | 1 | $28 |
| SPR Therapeutics, Inc | 3 | $24 |
| Globus Medical | 1 | $24 |
| Averitas Pharma Inc. | 1 | $23 |
| GRT US Holding, Inc. | 1 | $22 |
| Electronic Waveform Lab, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Painteq LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza Spinal Cord Stimulation System$8,109
- SYNCHROMEDII$509
- INTELLIS ADAPTIVESTIM$463
- Prospera$401
- Omnia$314
- ETERNA$256
- SPECTRA WAVEWRITER$159
- Evoke$123
- GENERAL PAIN MANAGEMENT$116
- SYNCHROMED$109
- Superion ISS$108
- SUPERION$102
How this compares
$22,305 in reported general payments places this provider in the 80th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,360 | $40,629 |
| OxycontinOxycodone Hcl | 31 | $16,604 |
| Xtampza ErOxycodone Myristate | 20 | $13,535 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 410 | $11,256 |
| Fentanyl | 120 | $7,463 |
| Morphine Sulfate ErMorphine Sulfate | 105 | $3,072 |
| Gabapentin | 265 | $2,972 |
| Pregabalin | 122 | $2,936 |
| Tizanidine Hcl | 315 | $2,907 |
| Oxycodone Hcl | 103 | $2,157 |
| Tramadol Hcl | 219 | $1,560 |
| Methocarbamol | 106 | $1,402 |
| Cyclobenzaprine Hcl | 94 | $1,003 |
| Hydromorphone Hcl | 100 | $961 |
| Methadone Hcl | 46 | $685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $673 | $13,53520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Rockwall
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Genaro GutierrezAustin$1.3M
- Chad StephensSouthlake$1.1M
- Ioannis SkaribasHouston$979K
- Duane GriffithTyler$730K
- Brannon FrankAustin$698K
- Robert WillsRound Rock$692K
- Ankur KhoslaShenandoah$511K
- Brian RichDecatur$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.